X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (528) 528
male (396) 396
index medicus (359) 359
animals (319) 319
pharmacology & pharmacy (300) 300
indans - pharmacology (295) 295
indans - pharmacokinetics (282) 282
indans - therapeutic use (257) 257
female (232) 232
donepezil (222) 222
indans - administration & dosage (193) 193
rats (176) 176
indans - adverse effects (168) 168
alzheimer disease - drug therapy (167) 167
aged (162) 162
alzheimer's disease (161) 161
piperidines - therapeutic use (150) 150
adult (139) 139
dose-response relationship, drug (136) 136
double-blind (134) 134
piperidines - pharmacokinetics (132) 132
middle aged (131) 131
alzheimers-disease (123) 123
piperidines - pharmacology (116) 116
cholinesterase inhibitors - therapeutic use (112) 112
indans - chemistry (109) 109
treatment outcome (104) 104
neurosciences (101) 101
cholinesterase inhibitors - pharmacology (98) 98
cholinesterase inhibitors - pharmacokinetics (93) 93
piperidines - administration & dosage (90) 90
pharmacokinetics (89) 89
piperidines - adverse effects (88) 88
indans - blood (85) 85
mice (84) 84
psychiatry (81) 81
double-blind method (76) 76
rats, sprague-dawley (74) 74
clinical neurology (73) 73
analysis (71) 71
drug therapy (70) 70
administration, oral (69) 69
efficacy (69) 69
cholinesterase inhibitors - adverse effects (67) 67
aged, 80 and over (66) 66
dementia (66) 66
cholinesterase inhibitors - administration & dosage (65) 65
placebo-controlled trial (64) 64
cholinesterase-inhibitors (61) 61
acetylcholinesterase (59) 59
chemistry, medicinal (59) 59
safety (58) 58
drug interactions (57) 57
rivastigmine (55) 55
time factors (53) 53
brain - metabolism (50) 50
parkinson disease - drug therapy (50) 50
indans - metabolism (49) 49
parkinson's disease (49) 49
piperidines - blood (49) 49
geriatrics & gerontology (47) 47
chemistry, analytical (46) 46
rasagiline (46) 46
research (46) 46
biochemistry & molecular biology (45) 45
nootropic agents - therapeutic use (44) 44
pharmacology/toxicology (44) 44
brain - drug effects (43) 43
drug therapy, combination (43) 43
rats, wistar (42) 42
clinical trials as topic (41) 41
reproducibility of results (41) 41
structure-activity relationship (41) 41
toxicology (41) 41
alzheimers disease (38) 38
cholinesterase inhibitors (38) 38
cross-over studies (38) 38
piperidines - chemistry (38) 38
acetylcholinesterase inhibitor (37) 37
area under curve (37) 37
drugs (37) 37
severity of illness index (37) 37
young adult (37) 37
drug administration schedule (36) 36
indacaterol (36) 36
care and treatment (35) 35
pharmacology (35) 35
cognition - drug effects (34) 34
galantamine - therapeutic use (34) 34
memantine (34) 34
acetylcholinesterase - metabolism (33) 33
biological availability (33) 33
disease models, animal (33) 33
drug combinations (33) 33
galantamine (33) 33
indans - chemical synthesis (33) 33
adolescent (32) 32
chemistry, organic (32) 32
quinolones - administration & dosage (32) 32
quinolones - pharmacokinetics (32) 32
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (735) 735
German (4) 4
Japanese (3) 3
Chinese (2) 2
Russian (2) 2
Spanish (2) 2
French (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacokinetics, ISSN 0312-5963, 04/2013, Volume 52, Issue 4, pp. 225 - 241
With the aging population and its rapidly increasing prevalence, dementia has become an important public health concern in developed and developing countries.... 
SELECTIVE-INHIBITION | STEADY-STATE PHARMACOKINETICS | APOLIPOPROTEIN-E EPSILON-4 | IN-VIVO | NMDA RECEPTOR ANTAGONIST | DONEPEZIL HCL | PHARMACOLOGY & PHARMACY | SINGLE-NUCLEOTIDE POLYMORPHISM | CHOLINESTERASE-INHIBITORS | ACETYLCHOLINESTERASE INHIBITORS | CLINICAL-PRACTICE | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Cholinesterase Inhibitors - pharmacokinetics | Excitatory Amino Acid Antagonists - therapeutic use | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Galantamine - pharmacokinetics | Phenylcarbamates - pharmacokinetics | Indans - therapeutic use | Galantamine - pharmacology | Piperidines - pharmacology | Rivastigmine | Piperidines - pharmacokinetics | Memantine - pharmacokinetics | Memantine - pharmacology | Pharmacogenetics | Phenylcarbamates - therapeutic use | Alzheimer Disease - drug therapy | Excitatory Amino Acid Antagonists - pharmacology | Phenylcarbamates - pharmacology | Cholinesterase Inhibitors - pharmacology | Galantamine - therapeutic use | Piperidines - therapeutic use | Alzheimer Disease - metabolism | Alzheimer Disease - genetics | Cholinesterase Inhibitors - therapeutic use | Memantine - therapeutic use | Indans - pharmacokinetics | Aging - metabolism | Indans - pharmacology | Physiological aspects | Usage | Drug therapy | Alzheimer's disease | Analysis
Journal Article
Progress in Neuropsychopharmacology & Biological Psychiatry, ISSN 0278-5846, 08/2016, Volume 69, pp. 49 - 59
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2013, Volume 53, Issue 10, pp. 1078 - 1090
Journal Article
Journal Article
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 2, pp. 147 - 155
Objective: Indacaterol/glycopyrronium (IND/GLY) is a once-daily fixed-dose combination of two long-acting bronchodilators: indacaterol 110 mu g (longacting... 
Chinese population | Indacaterol | Pharmacokinetics | Fixed-dose combination | Glycopyrronium | OBSTRUCTIVE PULMONARY-DISEASE | indacaterol | EFFICACY | QVA149 INDACATEROL/GLYCOPYRRONIUM | PARALLEL-GROUP | pharmacokinetics | glycopyrronium | PHARMACOLOGY & PHARMACY | fixed-dose combination | COPD | Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Area Under Curve | Humans | Muscarinic Antagonists - adverse effects | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Young Adult | Quinolones - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - pharmacokinetics | China | Adult | Female | Indans - administration & dosage | Muscarinic Antagonists - pharmacokinetics | Bronchodilator Agents - adverse effects | Glycopyrrolate - adverse effects | Drug Administration Schedule | Administration, Inhalation | Respiratory Tract Absorption | Glycopyrrolate - pharmacokinetics | Muscarinic Antagonists - administration & dosage | Asian Continental Ancestry Group | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Models, Biological | Bronchodilator Agents - pharmacokinetics | Adrenergic beta-2 Receptor Agonists - administration & dosage | Drug Combinations | Indans - pharmacokinetics | Nebulizers and Vaporizers
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 03/2013, Volume 168, Issue 6, pp. 1506 - 1518
Background The SH2-containing inositol-5-phosphatase 1 (SHIP1) metabolizes PI(3,4,5)P3 to PI(3,4)P2. SHIP1-deficient mice exhibit progressive inflammation.... 
cell motility